Cosmetic Implants Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented by Product Type (Dental Implants, Breast Implants, Facial Implants, Others), By Material Type (Polymers, Metals, Ceramics, Others), By Region 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 14.88 Billion
CAGR (2026-2031)	8.87%
Fastest Growing Segment	Dental Implants
Largest Market	North America
Market Size (2031)	USD 24.78 Billion

Market Overview

The Global Cosmetic Implants Market will grow from USD 14.88 Billion in 2025 to USD 24.78 Billion by 2031 at a 8.87% CAGR. Cosmetic implants are medical devices composed of biocompatible materials designed for surgical insertion to augment physical features or correct deformities. The market is primarily driven by an aging global population seeking aesthetic rejuvenation and the increasing societal acceptance of cosmetic interventions. Additionally, continuous advancements in material safety and durability encourage wider adoption by reducing the risk of rejection and improving patient outcomes.

One significant challenge that could impede market expansion involves the stringent regulatory requirements and safety concerns associated with extended implant use. High procedural costs and the risk of postsurgical complications may also deter potential patients from undergoing these elective surgeries. According to the International Society of Aesthetic Plastic Surgery, in 2024, plastic surgeons performed over 17.4 million surgical procedures globally. This data highlights the substantial scale of the aesthetic sector even amidst complex regulatory and economic environments.

Key Market Drivers

The Rising Prevalence of Dental Disorders and Traumatic Injuries is a primary catalyst propelling the Global Cosmetic Implants Market. As rates of periodontal disease, sports-related trauma, and age-related tooth loss escalate, the demand for restorative solutions like dental implants has surged significantly. These implants are increasingly viewed not just as medical necessities but as essential aesthetic restorations, driving patients to seek long-term biocompatible solutions. This trend is financially evident in the performance of major industry players; according to the Straumann Group, February 2024, in the 'Annual Report 2023', the company achieved a full-year revenue of CHF 2.4 billion, reflecting the robust global uptake of implantology and orthodontic solutions.

Simultaneously, the Increasing Incidence of Breast Cancer Necessitating Reconstructive Surgeries is a critical driver expanding the market for breast implants. The diagnosis of invasive cancer often leads to mastectomies, after which a significant portion of patients opt for immediate or delayed reconstruction to restore physical appearance and psychological well-being. According to the American Cancer Society, January 2024, in the 'Cancer Facts & Figures 2024' report, an estimated 310,720 new cases of invasive breast cancer were predicted to be diagnosed among women in the US alone for the year. This high incidence rate underscores the urgent and growing need for medical-grade aesthetic devices. Highlighting the immense scale of the sector's potential, the Straumann Group notably estimated in their 2023 report that the global addressable market for tooth replacement and orthodontic solutions grew to above CHF 19 billion in 2023.

Download Free Sample Report

Key Market Challenges

A significant impediment to the Global Cosmetic Implants Market involves the safety concerns and risks of postsurgical complications associated with extended implant use. While advancements are made, the physical reality that implants are not always lifetime devices creates hesitation among potential consumers. The fear of adverse events, such as capsular contracture, rupture, or systemic symptoms often referred to as breast implant illness, acts as a powerful deterrent. This apprehension directly hampers market growth by increasing the psychological threshold for entry, as patients weigh the initial aesthetic benefits against the probability of future revision surgeries and health risks.

The scale of this issue is reflected in the volume of corrective procedures required for existing patients. According to the American Society of Plastic Surgeons, in 2024, member surgeons performed 41,271 breast implant removal procedures specifically for augmentation patients. This figure highlights a substantial segment of the market dedicated not to new insertions, but to the extraction of devices due to complications or shifting patient preferences. Such data reinforces consumer skepticism regarding the longevity and biocompatibility of these products, thereby stalling the broader adoption of cosmetic implants.

Key Market Trends

The adoption of 3D-printed patient-specific implants is revolutionizing the sector by offering customized solutions that match unique patient anatomy with high precision, particularly in craniomaxillofacial and dental reconstructions. This technology utilizes digital workflows and additive manufacturing to produce implants that reduce surgical duration and improve aesthetic alignment compared to off-the-shelf alternatives. The surging demand for these personalized medical devices is financially evident in the performance of leading technology providers. According to Materialise NV, February 2024, in the 'Fourth Quarter and Full Year 2023 Results', revenue from its Medical segment grew by 19.5% to €101.4 million for the year ended December 31, 2023, reflecting the accelerated integration of 3D planning software and surgical guides into clinical practice.

Innovation in lightweight and ergonomic breast implants is simultaneously reshaping consumer preferences as patients increasingly prioritize safety and natural-feeling devices over traditional silicone options. Manufacturers are introducing proprietary surface textures and lighter filler materials designed to minimize complications such as capsular contracture and bottoming out, directly addressing long-standing concerns regarding implant weight and tissue stress. This shift toward advanced, biocompatible aesthetic solutions has generated significant commercial traction globally. According to Establishment Labs, February 2024, in the 'Fourth Quarter and Full Year 2023 Financial Results', the company reported a full-year revenue of $165.2 million, highlighting the robust market uptake of its next-generation Motiva implants even amidst a challenging economic landscape.

Segmental Insights

The Dental Implants segment is currently recognized as the fastest-growing category within the Global Cosmetic Implants Market. This expansion is primarily driven by the rising prevalence of periodontal diseases and tooth loss among the aging population, which necessitates effective restorative solutions. Additionally, a shifting patient preference toward long-term aesthetic improvements over traditional dentures is fueling this trend. Insights from the American Academy of Implant Dentistry emphasize the significant clinical need for permanent tooth replacements, reinforcing the widespread demand for these procedures. Consequently, continuous advancements in biocompatible materials and digital planning tools are further accelerating market adoption globally.

Regional Insights

North America maintains a leading position in the global cosmetic implants market, driven primarily by the widespread acceptance of aesthetic procedures and the presence of established healthcare facilities. The region benefits significantly from a robust regulatory environment, where the U.S. Food and Drug Administration enforces strict guidelines that enhance product safety and consumer trust. Additionally, the concentration of major medical device manufacturers within the United States facilitates continuous product development and accessibility. High healthcare expenditure and the availability of skilled plastic surgeons further support the sustained demand for cosmetic solutions across the region.

Recent Developments

• In September 2024, Establishment Labs Holdings Inc. announced that it received approval from the U.S. Food and Drug Administration (FDA) for its Motiva SmoothSilk Ergonomix and Round breast implants. This regulatory milestone allowed the company to commercialize its proprietary implant technology in the United States for both primary and revision breast augmentation procedures. The decision was supported by results from a robust investigational device exemption (IDE) study, which demonstrated improved biocompatibility and exceptionally low complication rates compared to industry standards. This development marked a pivotal expansion for the company into the world's largest market for cosmetic and reconstructive implants.
• In August 2024, CollPlant Biotechnologies and Stratasys Ltd. initiated a pre-clinical study to evaluate commercial-sized, 3D-bioprinted regenerative breast implants. The research collaboration utilized plant-based recombinant human collagen bio-inks and advanced 3D printing technology to fabricate 200cc implants designed to promote natural tissue growth. The study aimed to assess the ability of these bioprinted scaffolds to regenerate breast tissue and fully degrade over time, offering a potential alternative to traditional synthetic silicone devices. This initiative represented a significant step forward in the development of regenerative solutions for the global cosmetic and reconstructive implant market.
• In April 2024, Tiger Aesthetics Medical, LLC acquired substantially all assets associated with the breast implant business of Sientra, Inc. following the latter's Chapter 11 bankruptcy filing. The transaction, which involved a cash consideration of $42.5 million, enabled the acquiring firm to integrate a well-established portfolio of surgical assets into its own regenerative medicine division. The deal ensured the continued availability of the implants to plastic surgeons and patients while honoring existing warranties. This strategic consolidation was designed to strengthen the company's position in the aesthetic and reconstructive surgery market by combining traditional devices with tissue engineering capabilities.
• In April 2024, GC Aesthetics introduced the Luna XT anatomical breast implant, becoming the first manufacturer to launch a silicone breast implant approved under the new European Medical Device Regulation (MDR). This product release highlighted the company's compliance with the stricter safety, transparency, and clinical evidence standards required by the updated European regulatory framework. The device was engineered with a specialized microtextured surface and a cohesive silicone gel to support women undergoing breast reconstruction and augmentation. The launch underscored the organization's commitment to meeting rigorous regulatory benchmarks while expanding its portfolio of advanced aesthetic solutions.

Key Market Players

• 3M Company
• Polytech Health & Aesthetics GmbH
• Sientra Inc.
• GC Aesthetics Plc.
• Danaher Corporation
• Dentsply Sirona Inc.
• Zimmer Biomet Holdings Inc.
• AbbVie Inc.
• Henry Schein Inc.
• Straumann AG

By Material Type	By Region
Polymers Metals Ceramics Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Cosmetic Implants Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Cosmetic Implants Market, By Material Type:

• Polymers
• Metals
• Ceramics
• Others

• Cosmetic Implants Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE